Tidal Investments LLC Has $14.89 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Tidal Investments LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 190,305 shares of the biopharmaceutical company’s stock after purchasing an additional 22,707 shares during the period. Tidal Investments LLC’s holdings in Halozyme Therapeutics were worth $14,895,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. Horizon Investment Services LLC acquired a new position in Halozyme Therapeutics during the 2nd quarter worth about $2,254,000. Chase Investment Counsel Corp bought a new position in shares of Halozyme Therapeutics during the second quarter worth about $2,035,000. Mizuho Markets Americas LLC raised its position in shares of Halozyme Therapeutics by 270.8% during the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after acquiring an additional 926,526 shares during the last quarter. Great Lakes Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $2,821,000. Finally, Aurora Investment Counsel acquired a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $1,427,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

HALO has been the subject of a number of recent analyst reports. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Citizens Jmp upped their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Finally, TD Cowen boosted their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,478 shares of company stock worth $3,076,604 over the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $107.00 on Friday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $111.15. The company has a fifty day moving average of $93.18 and a 200-day moving average of $76.75. The firm has a market capitalization of $12.14 billion, a P/E ratio of 31.94, a P/E/G ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.